Changes in Hong Kong stocks | Hansite-B (03378) rose more than 4% and recently plans to establish a next-generation AI-driven innovative drug development paradigm with Huake Frontier Interdisciplinary Research Center

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that Hansai Tai-B (03378) rose more than 4%. As of press release, it had risen 4.23% to HK$27.1, with a turnover of HK$5.263,200.

According to the news, recently, Hansi Aite-B issued an announcement. In order to give full play to the advantages of industry-university-research integration and accelerate biomedical R&D innovation, the company officially signed the “Joint Laboratory for Artificial Intelligence Drug Research and Development” with the Huake-Australian City University Advanced Research Center. Relying on the AI platform of Huake's Frontier Interdisciplinary Research Center, as well as Hansatec's rich experience in innovative drug development and deep knowledge in the field of diseases, the two sides will cooperate deeply on antibody discovery and molecular design to jointly create a next-generation AI-driven innovative drug development paradigm.

This cooperation mainly includes the following two major directions. First, large-scale antibody banks are digitally screened and affinity maturity predicted using multi-scale molecular dynamics simulations and deep learning models in collaboration with cutting-edge interdisciplinary research centers. The antibody discovery cycle is greatly shortened, the specificity and binding efficiency of candidate antibodies to targets are improved, and the trial and error costs of traditional wet experiments are reduced. Second, the two sides will jointly develop and apply advanced AI generative models to carry out “De Novo Design” (De Novo Design) of cutting-edge molecules. Through intelligent prediction and multi-target optimization of molecular structure, physico-chemical properties, and ADME (absorption, distribution, metabolism, excretion, and toxicity) properties, the identification of the most promising drug candidate molecules is accelerated.